Table 13.
GRADE Evidence Profile comparing infliximab and cyclosporine vs. placebo for decreasing short-term risk of colectomy, in patients hospitalized with corticosteroid-refractory acute severe ulcerative colitis
|
Infliximab compared to Placebo for Hospitalized Patients with Acute Severe Ulcerative Colitis, refractory to intravenous corticosteroids | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Study event rates (95% CI) | Relative effect (95% CI) | Absolute effect* | No of participants (studies) | Quality of the evidence (GRADE) | |
| Short-term colectomy | 14/21 (66.7%) | 7/24 (29.2%) | RR 0.44 (0.22 to 0.87) | 373 fewer per 1,000 (from 520 fewer to 87 fewer) | 45 (1 RCTs) | ⨁⨁⨁◯1 MODERATE |
|
Cyclosporine compared to Placebo for Hospitalized Patients with Acute Severe Ulcerative Colitis, refractory to intravenous corticosteroids | ||||||
| Outcomes | Study event rates (95% CI) | Relative effect (95% CI) | Absolute effect* | No of participants (studies) | Quality of the evidence (GRADE) | |
| Short-term colectomy | 4/9 (44.4%) | 3/11 (27.3%) | RR 0.61 (0.18 to 2.01) | 173 fewer per 1,000 (from 364 fewer to 471 more) | 20 (1 RCTs) | ⨁⨁◯◯1 LOW |
|
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1
Rated down for imprecision due to low number of events
2
Rated down for very serious imprecision (very wide confidence intervals)